Amarantus Bioscience Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. It has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Companyâ€™s wholly owned subsidiary Cutanogen Corporation. The Companyâ€™s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

20-07-27	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI
20-01-29	Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	CI

Market Cap	2.11M 1.84M 1.74M 1.58M 2.95M 202M 2.97M 20.8M 8.03M 103M 7.92M 7.75M 331M	P/E 2014	-2.06x	P/E 2015	-0.15x
Enterprise Value	5.07M 4.42M 4.18M 3.79M 7.11M 487M 7.14M 50.04M 19.31M 248M 19.06M 18.64M 796M	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

20-07-27	Todos Medical Ltd. (OTCPK:TOMD.F) completed the acquisition of remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc.	CI
20-01-29	Amarantus BioScience Holdings, Inc. acquired majority interest in Hempori, Inc. for $0.38 million.	CI
20-01-02	Amarantus Completes Sublicense of ESS, MANF and Phenoguard to Emerald Organic Products	CI
19-11-21	Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary Manf Therapeutics	CI
19-10-24	Amarantus Bioscience Holdings, Inc. Enters into Agreement to License Diverse Therapeutics Portfolio to CBD-Focused Emerald Organic Products with Emerald Organic Growth, Inc	CI
19-10-23	Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	CI
19-06-25	Amarantus Enters into Letter of Intent with the Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation	CI
19-06-18	Amarantus BioScience Holdings, Inc. Announces Positive Pre-Clinical Data for Manf in Wolfram Syndrome	CI
19-05-28	Amarantus Hires Evolution Venture Partners To Evaluate Alternatives For Expansion Into Legal Hemp	CI
19-04-21	Todos Medical Ltd. (OTCPK:TOMD.F) exercised the option to acquire the remaining 80.01% stake in Breakthrough Diagnostics Inc. from Amarantus BioScience Holdings, Inc..	CI
19-01-11	Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries	CI
18-12-03	Todos Medical Ltd. Enters into Joint Venture Agreement with Amarantus to Develop Alzheimer’S Blood Diagnostic Lympro Test 2.0	CI
18-11-27	Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..	CI

21-11-18	Amarantus BioScience : Notification of Late Filing	PU
20-07-28	Amarantus BioScience : Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus	AQ
20-05-08	Emerald Organic Products : Restructures Joint Venture Agreement With Todos Medical by Entering Joint Collaboration Agreement	AQ
20-03-17	Amarantus BioScience : Todos Medical and 3DMed Enter Into Coronavirus (COVID-19) and Influenza A/B Testing Kit Distribution Agreement in US and Israel	AQ
20-02-06	Amarantus BioScience : Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International	AQ

Director	Title	Age	Since
John Commissiong BRD	Director/Board Member	81	2008-01-13
Robert Harris BRD	Director/Board Member	81	2010-11-30

Amarantus Bioscience Holdings Inc Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation: Amarantus Bioscience Holdings Inc

Latest news: Amarantus Bioscience Holdings Inc

Press Releases: Amarantus Bioscience Holdings Inc

Managers and Directors: Amarantus Bioscience Holdings Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.95%	+2.71%	+0.44%	+23.80%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+29.70%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+542.28%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+81.93%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.57%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+140.41%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+0.84%	+8.12%	+22.19%	+36.16%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-1.16%	+3.76%	+53.72%	+127.98%	29.15B
Weighted average by Cap.	-1.10%	+1.87%	+68.04%	+137.66%

	2014	2015
Net sales	-	-
Net income	-27.28M -23.79M -22.46M -20.39M -38.21M -2.62B -38.37M -269M -104M -1.33B -102M -100M -4.28B	-25.21M -21.99M -20.76M -18.85M -35.32M -2.42B -35.47M -249M -95.96M -1.23B -94.72M -92.61M -3.96B
Net Debt	-89K -77.61K -73.28K -66.54K -125K -8.54M -125K -878K -339K -4.34M -334K -327K -13.97M	2.96M 2.59M 2.44M 2.22M 4.15M 285M 4.17M 29.24M 11.28M 145M 11.14M 10.89M 465M

End-of-day quote OTC Bulletin Board
- ^USD	-